{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:42:28Z","timestamp":1792636948041,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,9,3]],"date-time":"2015-09-03T00:00:00Z","timestamp":1441238400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s00520-015-2904-5","type":"journal-article","created":{"date-parts":[[2015,9,2]],"date-time":"2015-09-02T01:47:30Z","timestamp":1441158450000},"page":"447-455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":127,"title":["Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer"],"prefix":"10.1007","volume":"24","author":[{"given":"Alison T.","family":"Stopeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Carducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Diel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Tonkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kueppers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Karsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Yardley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Maniar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Arellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,3]]},"reference":[{"key":"2904_CR1","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1200\/JCO.2010.33.2742","volume":"28","author":"MG Kris","year":"2010","unstructured":"Kris MG, Benowitz SI, Adams S, Diller L, Ganz P, Kahlenberg MS, Le QT, Markman M, Masters GA, Newman L, Obel JC, Seidman AD, Smith SM, Vogelzang N, Petrelli NJ (2010) Clinical cancer advances 2010: annual report on progress against cancer from the American society of clinical oncology. J Clin Oncol 28:5327\u20135347","journal-title":"J Clin Oncol"},{"key":"2904_CR2","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082\u20133092","journal-title":"Eur J Cancer"},{"key":"2904_CR3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813\u2013822","journal-title":"Lancet"},{"key":"2904_CR4","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132\u20135139","journal-title":"J Clin Oncol"},{"key":"2904_CR5","doi-asserted-by":"crossref","unstructured":"Fallowfield L, Cleeland CS, Body JJ, Stopeck A, von Moos R, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Ying W, Braun A, Cong Z (2011) Pain severity and analgesic use associated with skeletal-related events in patients with advanced breast cancer and bone metastases. Cancer Res 71(Suppl 3):Abstract P4-13\u201301","DOI":"10.1158\/0008-5472.SABCS11-P4-13-01"},{"key":"2904_CR6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165\u2013176","journal-title":"Cancer Treat Rev"},{"key":"2904_CR7","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/07357907.2010.483508","volume":"28","author":"NS Tchekmedyian","year":"2010","unstructured":"Tchekmedyian NS, Chen YM, Saad F (2010) Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors. Cancer Investig 28:849\u2013855","journal-title":"Cancer Investig"},{"key":"2904_CR8","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.bone.2012.05.010","volume":"51","author":"ST Chang","year":"2012","unstructured":"Chang ST, Tenforde AS, Grimsrud CD, O\u2019Ryan FS, Gonzalez JR, Baer DM, Chandra M, Lo JC (2012) Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy. Bone 51:524\u2013527","journal-title":"Bone"},{"key":"2904_CR9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ncponc0688","volume":"4","author":"CR Dunstan","year":"2007","unstructured":"Dunstan CR, Felsenberg D, Seibel MJ (2007) Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 4:42\u201355","journal-title":"Nat Clin Pract Oncol"},{"key":"2904_CR10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","volume":"14","author":"D Amadori","year":"2013","unstructured":"Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI (2013) Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 14:663\u2013670","journal-title":"Lancet Oncol"},{"key":"2904_CR11","doi-asserted-by":"crossref","unstructured":"Coleman RE, Wright J, Houston S, Agrawal R, Purohit OP-K, Hayward L, Simmonds P, Waterhouse A, Marshall H, BISMARK Investigators (2012) Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer. J Clin Oncol 30(Suppl):Abstract 511","DOI":"10.1200\/jco.2012.30.15_suppl.511"},{"key":"2904_CR12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","volume":"23","author":"AO Hoff","year":"2008","unstructured":"Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826\u2013836","journal-title":"J Bone Miner Res"},{"key":"2904_CR13","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Bhoomi M, O\u2019Ryan F (2014) American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update. J Oral Maxillofac Surg 72:1938\u20131956","journal-title":"J Oral Maxillofac Surg"},{"key":"2904_CR14","unstructured":"Hortobagyi G, Lipton A, Chew H, Gradishar W, Sauter N, Mohanlal R, Zheng M, McGrain B, Van Poznak C (2014) Efficacy and safety of continued zoledronic acid every 4\u00a0weeks versus every 12\u00a0weeks in women with bone metastases from breast cancer: results of the optimize-2 trial. J Clin Oncol 32(Suppl):Abstract LBA9500"},{"key":"2904_CR15","unstructured":"Cancer and Leukemia Group B (2012) Zoledronic acid in treating patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with bone involvement. ClinicalTrials.gov . http:\/\/clinicaltrials.gov\/show\/NCT00869206 . Accessed 01 December 2014"},{"key":"2904_CR16","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1158\/1078-0432.CCR-11-2944","volume":"18","author":"S Doshi","year":"2012","unstructured":"Doshi S, Sutjandra L, Zheng J, Sohn W, Peterson M, Jang G, Chow AT, Perez-Ruixo JJ (2012) Denosumab dose selection for patients with bone metastases from solid tumors. Clin Cancer Res 18:2648\u20132657","journal-title":"Clin Cancer Res"},{"key":"2904_CR17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RG Russell","year":"2008","unstructured":"Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733\u2013759","journal-title":"Osteoporos Int"},{"key":"2904_CR18","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","volume":"27","author":"K Fizazi","year":"2009","unstructured":"Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S (2009) Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27:1564\u20131571","journal-title":"J Clin Oncol"},{"key":"2904_CR19","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/jbmr.1893","volume":"28","author":"L Gedmintas","year":"2013","unstructured":"Gedmintas L, Solomon D, Kim S (2013) Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 28:1729\u20131737","journal-title":"J Bone Miner Res"},{"key":"2904_CR20","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.4158\/EP12367.CR","volume":"19","author":"R Paparodis","year":"2013","unstructured":"Paparodis R, Buehring B, Pelley E, Binkley N (2013) A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract 19:e64\u2013e68","journal-title":"Endocr Pract"},{"key":"2904_CR21","volume-title":"Amgen Inc","author":"XGEVA\u00ae (denosumab) US Package Insert","year":"2014","unstructured":"XGEVA\u00ae (denosumab) US Package Insert (2014) Amgen Inc. Thousand Oaks, CA"},{"key":"2904_CR22","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carriere P, Dansey R (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341\u20131347","journal-title":"Ann Oncol"},{"key":"2904_CR23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","volume":"379","author":"MR Smith","year":"2012","unstructured":"Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damiao R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gomez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379:39\u201346","journal-title":"Lancet"},{"key":"2904_CR24","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","volume":"31","author":"MR Smith","year":"2013","unstructured":"Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl C (2013) Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 31:3800\u20133806","journal-title":"J Clin Oncol"},{"key":"2904_CR25","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100:2613\u20132621","journal-title":"Cancer"},{"key":"2904_CR26","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M, Zoledronic Acid Prostate Cancer Study Group (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879\u2013882","journal-title":"J Natl Cancer Inst"},{"key":"2904_CR27","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/tbj.12155","volume":"19","author":"AM Brufsky","year":"2013","unstructured":"Brufsky AM, Sereika SM, Mathew A, Tomifumi O, Singh V, Rosenzweig M (2013) Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: a retrospective study. Breast J 19:504\u2013511","journal-title":"Breast J"},{"key":"2904_CR28","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471\u20131479","journal-title":"J Bone Miner Res"},{"key":"2904_CR29","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1359\/jbmr.090810","volume":"25","author":"JJ Body","year":"2010","unstructured":"Body JJ, Lipton A, Gralow J, Steger GG, Gao G, Yeh H, Fizazi K (2010) Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res 25:440\u2013446","journal-title":"J Bone Miner Res"}],"updated-by":[{"DOI":"10.1007\/s00520-015-2985-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T00:00:00Z","timestamp":1445212800000}}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-2904-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-015-2904-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-2904-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T21:31:48Z","timestamp":1599514308000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-015-2904-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,3]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["2904"],"URL":"https:\/\/doi.org\/10.1007\/s00520-015-2904-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00520-015-2985-1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,3]]}}}